157 related articles for article (PubMed ID: 8272007)
1. False positive results in a neuroblastoma screening programme.
Bell S; Parker L; Craft AW; Dale G; McGill AC; Seviour J; Cole M; Smith J
Med Pediatr Oncol; 1994; 22(3):181-6. PubMed ID: 8272007
[TBL] [Abstract][Full Text] [Related]
2. Creatinine related reference ranges for urinary homovanillic acid and vanillylmandelic acid at 6 months of age.
Cole M; Parker L; Craft AW; Bell S; Dale G; McGill AC; Seviour JA; Smith J
Arch Dis Child; 1993 Mar; 68(3):376-8. PubMed ID: 8466241
[TBL] [Abstract][Full Text] [Related]
3. Serial measurement of urinary VMA and HVA levels from one infant: a study for neuroblastoma mass screening.
Sawada T; Numata K; Hirata S
J Pediatr Surg; 1992 Apr; 27(4):452-5. PubMed ID: 1522454
[TBL] [Abstract][Full Text] [Related]
4. Screening for neuroblastoma in the north of England.
Parker L; Craft AW; Dale G; Bell S; Cole M; McGill AC; Seviour JA; Smith J
BMJ; 1992 Nov; 305(6864):1260-3. PubMed ID: 1303649
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of screening for neuroblastoma in the north of England.
Craft AW; Parker L; Dale G; McGill AC; Seviour JA; Bell S; Cole M; Smith J
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):337-41. PubMed ID: 1456400
[TBL] [Abstract][Full Text] [Related]
6. Screening for neuroblastoma in the northern region of England. Laboratory aspects.
Seviour JA; McGill AC; Craft AW; Parker L; Bell S; Cole M; Smith J; Hawkins E; Brown J; Dale GA
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):332-6. PubMed ID: 1456399
[TBL] [Abstract][Full Text] [Related]
7. Urinary vanillylmandelic acid and homovanillic acid levels in randomly-sampled urine for the mass screening of neuroblastoma.
Nishi M; Miyake H; Takeda T; Takasugi N; Hanai J; Kawai T
Jpn J Clin Oncol; 1990 Sep; 20(3):268-70. PubMed ID: 2255102
[TBL] [Abstract][Full Text] [Related]
8. Measurement of urinary vanillylmandelic acid (VMA) and homovanillic acid (HVA) for diagnosis of neural crest tumors.
Sawada T
Pediatr Hematol Oncol; 1997; 14(4):291-3. PubMed ID: 9211532
[No Abstract] [Full Text] [Related]
9. Three years of experience with random urinary homovanillic and vanillylmandelic acid levels in the diagnosis of neuroblastoma.
Tuchman M; Ramnaraine ML; Woods WG; Krivit W
Pediatrics; 1987 Feb; 79(2):203-5. PubMed ID: 3808793
[TBL] [Abstract][Full Text] [Related]
10. A 5-year (1990-1994) neuroblastoma screening feasibility study in France. Methodology and preliminary observations.
Mathieu P; Frappaz D; Chauvin F; Combaret V; Vercherat M; Brunat-Mentigny M; David L; Esteve J; Favrot M; Fouillat V; Greffe J; Lasset C; Renaud P; Philip T
Early Hum Dev; 1996 Sep; 46(1-2):177-96. PubMed ID: 9019414
[TBL] [Abstract][Full Text] [Related]
11. Establishment of cut off values for vanillylmandelic acid and homovanillic acid in 24-hr urine accumulation during mass screening for neuroblastoma.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J
Jpn J Clin Oncol; 1987 Sep; 17(3):221-8. PubMed ID: 3669365
[TBL] [Abstract][Full Text] [Related]
12. Vanillylmandelic acid, homovanillic acid, and catecholamines in urine of infants with neuroblastoma 6- to 11-month-old.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J
Jpn J Clin Oncol; 1986 Dec; 16(4):351-5. PubMed ID: 3795531
[TBL] [Abstract][Full Text] [Related]
13. Thin-layer chromatography of urinary homovanillic acid and vanillylmandelic acid for large-scale neuroblastoma mass screening.
Auray-Blais C; Giguère R; Lemieux B
Med Pediatr Oncol; 1989; 17(5):364-7. PubMed ID: 2796851
[No Abstract] [Full Text] [Related]
14. Determination of homovanillic acid and vanillylmandelic acid in neuroblastoma screening by stable isotope dilution GC-MS.
Fauler G; Leis HJ; Huber E; Schellauf C; Kerbl R; Urban C; Gleispach H
J Mass Spectrom; 1997 May; 32(5):507-14. PubMed ID: 9180052
[TBL] [Abstract][Full Text] [Related]
15. Value of random urinary homovanillic acid and vanillylmandelic acid levels in the diagnosis and management of patients with neuroblastoma: comparison with 24-hour urine collections.
Tuchman M; Morris CL; Ramnaraine ML; Bowers LD; Krivit W
Pediatrics; 1985 Feb; 75(2):324-8. PubMed ID: 3969335
[TBL] [Abstract][Full Text] [Related]
16. A new urinary mass screening system for neuroblastoma in infancy by use of monoclonal antibodies against VMA and HVA.
Yokomori K; Hori T; Tsuchida Y; Kuroda M; Yoshioka M
J Pediatr Surg; 1989 Apr; 24(4):391-4. PubMed ID: 2659761
[TBL] [Abstract][Full Text] [Related]
17. Cases of neuroblastoma missed by the mass screening programs.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J; Kawai T
Pediatr Res; 1989 Dec; 26(6):603-7. PubMed ID: 2602040
[TBL] [Abstract][Full Text] [Related]
18. Mass screening for neuroblastoma in Miyagi Prefecture.
Itano M; Morita S; Fujie H; Ohashi Y; Minegishi N; Minegishi M; Yamaguchi Y; Sato T; Tsuchiya S; Konno T
Tohoku J Exp Med; 1992 Oct; 168(2):137-9. PubMed ID: 1306297
[TBL] [Abstract][Full Text] [Related]
19. Determination of urinary vanillylmandelic acid and homovanillic acid by high performance liquid chromatography for mass screening of neuroblastoma.
Sato Y; Hanai J; Takasugi N; Takeda T
Tohoku J Exp Med; 1986 Oct; 150(2):169-74. PubMed ID: 3810642
[TBL] [Abstract][Full Text] [Related]
20. Can mass screening for neuroblastoma detect patients with low vanillylmandelic acid and high homovanillic acid?
Nishi M; Miyake H; Takeda T; Takasugi N; Hanai J; Kawai T
Acta Paediatr Jpn; 1989 Dec; 31(6):742-4. PubMed ID: 2516402
[No Abstract] [Full Text] [Related]
[Next] [New Search]